W eight-loss drugs have made big headlines in health over the past year, and Eli Lilly’s drug tirzepatide (known as Zepbound ...

Goldman Sachs re-rated Eli Lilly and Novo Nordisk, citing potential for weight-loss drugs. Global sales expected to reach ...

So, could Eli Lilly be the next to enter the trillion-dollar club? It's very possible. The company has proven and continues ...

Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights.

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target ...

Ricks highlighted that the company is trying to prove the efficacy of its drugs for not only weight loss but also ...

Eli Lilly and Co., is more than doubling its investment in its Boone County manufacturing site to increase production of ...

Eli Lilly has shattered its investment pledge in Concord and already filled hundreds of jobs before production even starts.

Eli Lilly will invest an additional $5.3 billion into a new manufacturing site, boosting production for its weight loss and ...

The outlay to expand an Indiana production site, combined with a previous $3.7 billion commitment, is the largest ...

Eli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its ...

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.